Upcoming Healthcare Conference Featuring Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) has shared exciting news about its participation in the 2024 Cantor Fitzgerald Global Healthcare Conference. This significant event is set to unfold in New York City from September 17 to September 19.
Connecting with Investors
The Aurinia management team is looking forward to engaging with investors through a series of one-on-one meetings. Additionally, they'll be part of an enlightening fireside chat scheduled for Tuesday, September 17, at 3:05 PM EDT. This session is aimed at fostering a meaningful conversation between Aurinia's leadership and the investment community.
Information on the Live Webcast
If you can't make it to the event in person, don’t worry—there will be a live webcast of the fireside chat available in the Investor section of Aurinia's official website. This opportunity allows a wider audience to stay updated with the Company’s developments and insights.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals is dedicated to creating innovative treatments for patients facing autoimmune diseases, which often leave significant medical needs unaddressed. Their flagship product, LUPKYNIS® (voclosporin), is notable for being the first FDA-approved oral treatment specifically for adult patients suffering from active lupus nephritis.
Advancements in Autoimmune Disease Therapies
Currently, Aurinia isn't just resting on its current achievements; they are actively progressing with AUR200, a new therapy that shows potential as a best-in-class solution for autoimmune diseases. This groundbreaking treatment aims to target both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand), potentially offering new hope to individuals affected by these conditions.
Looking Ahead: Innovation and Growth
As Aurinia Pharmaceuticals expands its pipeline and improves its therapeutic offerings, the upcoming conference becomes a vital platform for sharing its vision and recent advancements with stakeholders. The interactions between Aurinia's management and investors at this event are expected to generate increased interest in the Company’s innovative solutions and reaffirm its commitment to enhancing treatment options.
Frequently Asked Questions
What is the purpose of the 2024 Cantor Fitzgerald Global Healthcare Conference?
The conference serves as a venue for healthcare companies like Aurinia to connect with investors and share their latest developments and strategies.
What is Aurinia's flagship product?
Aurinia’s flagship product is LUPKYNIS® (voclosporin), an FDA-approved oral therapy for lupus nephritis.
When will Aurinia present at the conference?
Aurinia's management will take part in a fireside chat on September 17, at 3:05 PM EDT.
How can I listen to the webcast of the presentation?
The webcast will be available through the Investor section of Aurinia's official website for those who can't attend in person.
What are the future prospects for Aurinia Pharmaceuticals?
Aurinia is concentrating on developing additional treatments, such as AUR200, to continue addressing unmet needs in the area of autoimmune diseases.